Substituted aryl cycloalkanol derivatives and methods of...

Details Substituted aryl cycloalkanol derivatives and methods of... Substituted aryl cycloalkanol derivatives and methods of...

2008-04-29

2008-04-29

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S399000, C544S403000

Reexamination Certificate

active

07365076

ABSTRACT:
The present invention is directed to substituted aryl cycloalkanoyl derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

REFERENCES:
patent: 3454554 (1969-07-01), Biel et al.
patent: 4221919 (1980-09-01), Grimova et al.
patent: 4229449 (1980-10-01), Melloni et al.
patent: 4310524 (1982-01-01), Wiech et al.
patent: 4535186 (1985-08-01), Husbands et al.
patent: 4826844 (1989-05-01), Husbands et al.
patent: 5502047 (1996-03-01), Kavey
patent: 6703389 (2004-03-01), Wong et al.
patent: 2002/0107249 (2002-08-01), Wong et al.
patent: 2004/0019101 (2004-01-01), Karlstadt et al.
patent: 2004/0143008 (2004-07-01), Deecher et al.
patent: 2004/0152710 (2004-08-01), Deecher et al.
patent: 2004/0180879 (2004-09-01), Deecher et al.
patent: 2556474 (2004-08-01), None
patent: 0 065 757 (1985-01-01), None
patent: 0 310 268 (1988-09-01), None
patent: 0 310 268 (1989-04-01), None
patent: 0 208 235 (1990-01-01), None
patent: 0 303 961 (1994-04-01), None
patent: 1 266 659 (2002-12-01), None
patent: 2005336172 (2005-12-01), None
patent: WO 91/18602 (1991-12-01), None
patent: WO 97/35586 (1997-10-01), None
patent: WO 99/44601 (1999-09-01), None
patent: WO 00/59851 (2000-10-01), None
patent: WO 01/01973 (2001-01-01), None
patent: WO 02/064543 (2002-08-01), None
patent: WO 02/064543 (2002-08-01), None
patent: WO 02/078691 (2002-10-01), None
patent: WO 03/037334 (2003-05-01), None
patent: WO 03/053426 (2003-07-01), None
patent: WO 03/077897 (2003-09-01), None
patent: 03/106443 (2003-12-01), None
patent: 03/106444 (2003-12-01), None
patent: WO 2004/016272 (2004-02-01), None
patent: 2004/035036 (2004-04-01), None
patent: 2004/035058 (2004-04-01), None
patent: 2006/055854 (2006-05-01), None
Svensson, T., Brain Noradrenaline and the Mechanisms of Action of Antidepressant Drugs, Acta Psychiatr. Scand., 101 (Suppl. 402): 18-27 (2000).
Bosker, et al., Future Antidepressants, CNS Drugs, 18(11), 705-732 (2004).
U.S. Appl. No. 60/557,651, filed Mar. 30, 2004, Kim et al.
U.S. Appl. No. 60/557,831, filed Mar. 30, 2004, Kim et al.
U.S. Appl. No. 60/569,863, filed May 11, 2004, Kim et al.
U.S. Appl. No. 60/569,861, filed May 11, 2004, Vu.
U.S. Appl. No. 10/963,458, filed Oct. 12, 2004, Mahaney et al.
U.S. Appl. No. 10/962,881, filed Oct. 12, 2004, Mahaney.
U.S. Appl. No. 10/963,064, filed Oct. 12, 2004, Trybulski et al.
U.S. Appl. No. 10/962,897, filed Oct. 12, 2004, Deecher et al.
U.S. Appl. No. 10/962,880, filed Oct. 12, 2004, Trybulski et al.
U.S. Appl. No. 10/962,971, filed Oct. 12, 2004, Mahaney et al.
U.S. Appl. No. 10/962,899, filed Oct. 12, 2004, Mahaney et al.
Clinical Trial: “Phase III Randomized Study of Medroxyprogesterone Versus Venlafaxine in Women With Symptomatic Hot Flashes”, www.clinicaltrials.gov sponsored by the National Institutes of Health, Study ID Numbers: CDR0000069217; NCCTG-N99C7; NCI-P02-0204, 2003, 6 pages.
Acs, N. et al., “Estrogen improves impaired musculocutaneous vascular adrenergic reactivity in pharmacologically ovariectomized rats: a potential peripheral mechanism for hot flashes?”,Endocrinology, 2001 15: 68-73.
Barlow, D. H., “Venlafaxine for hot flushes,”Lancet, Dec. 16, 2000, 356(9247): 2025-2026.
Barton, D. et al., “Hot Flashes—Aetiology and Management,”Drugs and Aging, 2001, 18(8): 597-606.
Berendsen, H. H. G., “Hot Flushes and serotonin,”Journal of the British Menopause Society, Mar. 2002, 8(1): 30-34.
Berendsen, H. H. G., “Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats,”European Journal of Pharmacology, 2001, 419(1): 47-54.
Berendsen, H. H. G., “The role of serotonin in hot flushes,”Maturitas, 2000, 36(3): 155-164.
Bundgaard, H., “Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs,”Advanced Drug Deliver Reviews, 1992, 8, 1-38.
Bundgaard, H. et al., “Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties,”J. of Pharmaceutical Sciences, Apr. 1988, 77(4):285-298.
Casper, R. F. et al., “Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism,”Clinical Endocrinology, 1985, 22: 293-312.
Fink, G. et al., “Oestrogen and mental state,”Nature, 1996, 383(6598): 306.
Freedman, R. R. et al., “Clonidine raises the sweating threshold in symptomatic but not asymptomatic postmenopausal women,”Fertility&Sterility, 2000, 74(1): 20-3.
Freedman, R. R., “Physiology of hot flashes,”American Journal of Human Biology, 2001, 13: 453-464.
French, N., “α2-Adrenoceptors and I2sites in the mammalian central nervous system,”Pharmacol. Ther., 1995, 68(2):175-208.
Janowsky, D. S. et al., “Desipramine: an overview,”Journal of Clinical Psychiatry, 1984, 45(10 Pt 2): 3-9.
Katovich, M. J. et al., “Mechanisms Mediating the Thermal Response to Morphine Withdrawal in Rats,”Proceedings of the Society for Experimental Biology&Medicine, 1990, 193(2): 129-35.
Katovich, M. J. et al., “Alpha-adrenergic mediation of the tail skin temperature response to naloxone in morphine-dependent rats,”Brain Research, 1987, 426: 55-61.
Krämer et al., In: Murphy et al.,3rdInt'l Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment-Proceedings, Paris, France: SCI: 3-7 1992.
Krogsgaard-Larsen, et al., (ed).Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191, 1991.
Kronenberg, F. et al., “Thermoregulatory Physiology of Menopausal Hot Flashes: A Review,”Can. J. Physiol. Pharmacol., 1987, 65:1312-1324.
Loprinzi, C.L. et al., “Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial,”Lancet, Dec. 16, 2000, 356(9247): 2059-2063.
Loprinizi, C. L. et al. “Pilot Evaluation of Venlafaxine Hydrochloride for the Therapy of Hot Flashes in Cancer Survivors,”Journal of Clinical Oncology, Jul. 1998, 16(7): 2377-2381.
Mackinnon et al., “α2-Adrenoceptors: more subtypes but fewer functional differences,”TIPS, 1994, 15: 119-123.
Merchenthaler et al., “The effect of estrogens and antiestrogens in a rat model for hot flush,”Maturitas, 1998, 30(3): 307-316.
Morin, S. M., “Atomoxetine Selectively Induces Fos Expression in the Rat Prefrontal Cortex,” Presented at Society for Neuroscience Annual Meeting (SFN); Nov. 2-7, 2002, Orlando, FL.
Pacholczyk, T. et al., “Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter,”Nature, 1991, 350(6316): 350-4.
Panek, D.U. et al., “Effect of continuous intraventricular estrogen or catechol estrogen treatment on catecholamine turnover in various brain regions,”J. Pharmacol. Exp. Ther., 1986, 236(3), 646-652.
Prasad, P.D., et al., “Functional expression of the plasma membrane serotonin transporter but not the vesicular monoamine transporter in human placental trophoblasts and choriocarcinoma cells,”Placenta, 1996, 17(4): 201-7.
Quella, S. K. et al., “Pilot evaluation of Venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer,”The Journal of Urology, Jul. 1999, 162: 98-102.
Reneric, J-Ph. et al., “Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhi

Affiliated with

Also associated with

Rating

Substituted aryl cycloalkanol derivatives and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted aryl cycloalkanol derivatives and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted aryl cycloalkanol derivatives and methods of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2744753